Q1 26 EPS
$-0.05
BEAT +50.00%
Est. $-0.10
Q1 26 Revenue
$12.5M
BEAT +9.13%
Est. $11.4M
vs S&P Since Q1 26
+37.4%
BEATING MARKET
APYX +43.1% vs S&P +5.7%
Market Reaction
Did APYX Beat Earnings? Q1 2026 Results
Apyx Medical Corp delivered a strong first quarter for fiscal 2026, beating Wall Street expectations on both the top and bottom lines and extending its streak of consensus EPS beats to four consecutive quarters. The medical device maker posted revenu… Read more Apyx Medical Corp delivered a strong first quarter for fiscal 2026, beating Wall Street expectations on both the top and bottom lines and extending its streak of consensus EPS beats to four consecutive quarters. The medical device maker posted revenue of $12.49 million, up 32.5% year over year and well ahead of the $10.77 million analyst estimate, while its per-share loss of $0.05 came in notably better than the $0.11 consensus forecast, a 54.55% positive surprise. The primary driver was the Surgical Aesthetics segment, which generated $10.73 million in revenue, fueled by domestic commercial momentum from the AYON Body Contouring System and a 62.9% surge in international revenue to $4.38 million, with South Korea emerging as a particularly promising new market following December 2025 regulatory approval. Gross margin expanded to 63.5% from 60.1% a year ago, reflecting a favorable mix shift toward higher-margin aesthetics products. Encouraged by the quarter's performance, management raised its full-year 2026 revenue guidance to $59.00 million to $60.00 million, up from the prior range of $57.50 million to $58.50 million.
Key Takeaways
- • Domestic sales of AYON Body Contouring System following Q3 2025 commercial launch
- • Increased international Renuvion generator sales
- • Higher single-use handpiece volumes in both domestic and international markets
- • Strong performance in South Korea following regulatory approval in December 2025
- • Gross margin expansion to 63.5% driven by favorable segment mix toward Surgical Aesthetics
- • OEM sales volume increases to existing customers
APYX YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
APYX Revenue by Segment
With YoY comparisons, source: SEC Filings
APYX Revenue by Geography
With YoY comparisons, source: SEC Filings
“Our first quarter results reflect continued execution against our commercial strategy, with strong revenue growth driven by adoption of AYON in the U.S., increasing demand for Renuvion internationally and an increase in handpieces worldwide.”
— Charlie Goodwin, Q1 2026 Earnings Press Release
APYX Earnings Trends
APYX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
APYX EPS Trend
Earnings per share: estimate vs actual
APYX Revenue Trend
Quarterly revenue: estimate vs actual
APYX Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $-0.08 | $-0.07 | +14.63% | $13.9M | +5.38% |
| Q1 26 BEAT | $-0.10 | $-0.05 | +50.00% | $12.5M | +9.13% |
| Q4 25 BEAT FY | $-0.06 | $-0.03 | +46.43% | $19.2M | +0.21% |
| FY Full Year | $-0.30 | $-0.27 | +11.18% | $52.8M | +1.19% |
| Q3 25 BEAT | $-0.10 | $-0.05 | +51.22% | $12.9M | +7.30% |
| Q2 25 BEAT | $-0.09 | $-0.09 | +0.00% | $11.4M | -2.79% |
| Q1 25 BEAT | $-0.12 | $-0.10 | +13.04% | $9.4M | +1.04% |